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YConclusion: Despite a greater risk of target vessel revascularization in patients
switched from clopidogrel to a Gen 2 APT, there was not an increased risk of stent
thrombosis. This data suggests that Gen 2 APT may be employed in higher risk
patients but do not increase the risk of stent thrombosis, implying adequate compli-
ance in these high-risk patients.
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Comparing the Procedural and 30-Day Outcomes in Patients with or without a History
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Background: In prior studies, patients with previous coronary artery bypass grafting
(CABG) experienced signiﬁcantly greater incidence of adverse clinical events upon
subsequent repeat CABG, percutaneous coronary intervention, or medical treatment,
compared to patients with no prior CABG. In this analysis, we evaluate the procedural and
30-day outcomes in patients with and without a history of previous CABG in the ORBIT
II Trial.
Methods: The ORBIT II Trial, a prospective, multicenter, non-blinded clinical trial
that enrolled 443 consecutive patients, was designed to evaluate the safety and efﬁcacy
of the coronary Orbital Atherectomy System to prepare de novo, severely calciﬁed
coronary lesions for stent placement. Procedural and 30-day outcomes in patients with
history of previous CABG (N¼65) and no history of CABG (N¼378) were evaluated
in this analysis.
Results: Compared to patients without history of previous CABG, patients with
history of CABG were more likely to be male (p¼0.005) and have a higher prevalence
of diabetes mellitus (p¼0.025), history of dyslipidemia (p¼0.008), hypertension
(p¼0.028), and myocardial infarction (MI) (p<0.0001). The rate of procedural success
(stent delivery with residual stenosis <50% without the occurrence of an in-hospital
major adverse cardiac event (MACE)) was similar 83.1% (previous CABG) and 89.9%
(without previous CABG) (p¼0.132). Statistically similar low rates of severe dissection
(7.7% vs. 2.6%: p¼0.054), perforation (0% vs. 2.1%: p¼0.611), persistent slow ﬂow
(0% vs. 1.1%: p¼1.0), and abrupt closure (3.1% vs. 1.6%: p¼0.333) were observed in
the history of CABG and no history of CABG groups, respectively. As estimated by
Kaplan Meier at 30-days, patients had similar low rates of MACE (previous CABG:
16.9% vs. without previous CABG: 9.3%, p¼0.070).
Conclusion: Preparation of severely calciﬁed coronary lesions with the coronary
Orbital Atherectomy System facilitated stent delivery in patients with a history of
previous CABG, resulting in low rates of 30-day MACE.CRT-129
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Background: Cardiovascular disease is common in patients with chronic kidney
disease (CKD) and often results in severely calciﬁed lesions that are difﬁcult to cross
and treat. As a result, this population may have worse clinical outcomes following
percutaneous coronary intervention compared to patients without CKD. Clinical trials
typically exclude this patient population.
Methods: ORBIT II patients with severely calciﬁed coronary lesions treated with the
coronary Orbital Atherectomy System (OAS) were divided into three groups based on
the estimated glomerular ﬁltration rate (eGFR, mL/min/1.73m2) at baseline: I (CKD
Stages 3-5), eGFR<60 (n¼115); II (CKD stages 1-2), eGFR 60 to <90 (n¼218);
and III (normal), eGFR90 (n¼108).
Results: Patients in groups I and II were older (p<0.0001), and there were more
females in these two groups than in group III (p¼0.0468). History of previous stroke
(p¼0.0351) was more prevalent in groups I and II. In addition, the total length of
calcium was signiﬁcantly longer in group II (p¼0.0003). Similar successful stent de-
livery occurred in 97.4%, 97.2% and 99.1% (p¼0.7006) of cases with <50% residual
stenosis in 99.1%, 98.2% and 99.1% (p¼0.8779) of subjects in groups I, II and III,
respectively. Statistically similar low rates of severe dissection (1.7%, 5.5%, 0.9%:
p¼0.0709), perforation (2.6%, 1.8%, 0.9%: p¼0.7343), persistent slow ﬂow (0.9%,
1.4%, 0.0%: p¼0.8110), and abrupt closure (1.7%, 1.8%, 1.9%: p¼1.0000) were
observed in groups I, II, and III, respectively. The 30 day Freedom from MACE rates
in groups I (87.8%), II (87.1%), and III (96.3%) were similar (p¼0.0555).
Conclusion: Severely calciﬁed coronary lesion pre-treatment with the coronary OAS
resulted in similar 30 day Freedom from MACE rates and low rates of procedural
complications in CKD patients compared with the non-CKD patients despite the
older demographic and longer length of calcium in the CKD patients.
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Background: Previous studies have shown a negative correlation between female
gender and adverse events after percutaneous coronary intervention (PCI). In this
analysis, we evaluate the procedural and 30-day outcomes of male and female patients
in the ORBIT II Trial.
Methods: The ORBIT II Trial, a prospective, multicenter, non-blinded clinical
trial that enrolled 443 consecutive patients, was designed to evaluate the safety and
efﬁcacy of the coronary Orbital Atherectomy System to prepare de novo, severely
calciﬁed coronary lesions for stent placement. Procedural and 30-day outcomes in
male patients (N¼286) were compared to female patients (N¼157). The primary
safety endpoint was freedom from major adverse cardiac events (MACE) at 30 days
post-procedure. The primary efﬁcacy endpoint was procedural success deﬁned as
stent delivery with a residual stenosis of <50% without the occurrence of an in-
hospital MACE.
Results: Compared to males, females were older (p¼0.0011) and had lower eGFR at
baseline (p¼0.0024). However males had a higher rate of previous coronary artery
bypass graft (p¼0.0048). Both males and females met the primary safety endpoint
goal of 83% (89.2% [95% CI: 85.5%-92.8%] vs. 90.4% [95% CI: 85.7%-95.2%]) and
primary efﬁcacy endpoint of 82% (88.4% [95% CI: 84.1%-91.9%] vs. 89.7% [95%
CI: 83.9%-94.0%]). As estimated by Kaplan Meier at 30-days, males and females
had similar low rates of MACE (10.8% vs. 9.6%, p¼0.6613), myocardial infarction
(MI) (10.1% vs. 8.9%, p¼0.666), target vessel revascularization/target lesion
